SEATTLE and VANCOUVER, British Columbia, Sept. 4, 2019 /CNW/ -- Achieve Life
Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical
company committed to the global development and commercialization
of cytisinicline for smoking cessation, today announced that
John Bencich, Chief Financial and
Operating Officer, will present at two upcoming investor
conferences.
- H.C. Wainwright 21st Annual Global Investment Conference on
Tuesday, September 10 at the Lotte
New York Palace Hotel
- Ladenburg Thalmann 2019 Healthcare Conference on Tuesday, September 24 at the Sofitel New
York
A live webcast can be accessed at
http://ir.achievelifesciences.com/events-and-webcasts. A replay of
the presentations will be archived on Achieve's website following
the conferences.
About Achieve
Tobacco use is currently the leading
cause of preventable death and is responsible for nearly seven
million deaths annually worldwide1. It is estimated that
28.7% of cancer deaths in the U.S. are attributable to cigarette
smoking2.
Achieve's focus is to address the global smoking health epidemic
through the development and commercialization of cytisinicline.
Cytisinicline is a plant-based alkaloid with a high binding
affinity to the nicotinic acetylcholine receptor. It is believed to
aid in smoking cessation by interacting with nicotine receptors in
the brain by reducing the severity of nicotine withdrawal symptoms
and by reducing the reward and satisfaction associated with
smoking.
As an approved, branded product in Central and Eastern Europe for more than two decades, it
is estimated that over 20 million people have used cytisinicline to
help combat nicotine addiction.
Achieve Contact
Jason
Wong
jwong@bplifescience.com
(415) 375-3340 ext. 4
1 World Health Organization. WHO Report on
the Global Tobacco Epidemic, 2017. Geneva: World Health Organization, 2017
2 Annals of Epidemiology , Volume 25 , Issue 3 ,
179 - 182.e1
View original content to download
multimedia:http://www.prnewswire.com/news-releases/achieve-life-sciences-announces-presentations-at-upcoming-investor-conferences-300910961.html
SOURCE Achieve Life Sciences, Inc.